SecBot SecBot

SKYE drug pipeline

Skye Bioscience, Inc. · 3 rated drugs
$1.07
−2.3% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
3
2 bearish · 1 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
▼ bearish
Impact
PhasePhase 2a
Time to marketLikely years away if ever; nimacimab is currently in Phase 2a (Part C expansion), with Phase 2b design under FDA review but not yet funded. The Redx reverse merger monetizes the asset via CVR — further development by Skye/Fibrx is uncertain.

nimacimab Updated Sep 13

What to watch

Monitor the Q4 2026 Part C expansion topline data for nimacimab, which could drive value in the CVR. However, with the Redx reverse merger pending (expected Q4 2026 close), pre-merger SKYE shares now primarily represent ~5.38% of the future Fibrx Therapeutics, with nimacimab upside limited to the CVR, extreme caution is warranted for equity holders.

Bull case
  • nimacimab showed strong 52-week data: 22.3% mean weight loss in combination with semaglutide, a result that rivals or exceeds current GLP-1 monotherapy outcomes.
  • As a peripheral CB1 inverse agonist, nimacimab has a novel mechanism orthogonal to GLP-1s, it could be a best-in-class oral or injectable add-on to existing obesity therapies.
  • Analyst consensus remains bullish: 9 Buy/Strong Buy vs 3 Hold (0 Sell), with a mean price target of ~$68, median $48, and high of $160 (per latest snapshot as of Sep 2026).
Bear case
  • Skye announced a reverse merger with Redx Pharma on Aug 14, 2026; pre-transaction SKYE shareholders will own just ~5.38% of the combined Fibrx Therapeutics, representing extreme dilution, nimacimab is no longer the company's core asset, just a CVR.
  • Cash runway only through Q4 2026 (excluding Phase 2b costs); the company had just $17.1M as of March 2026, raising serious financing risk for further nimacimab development.
  • Significant insider selling by major holder 5AM Ventures (over 370K shares at ~$0.32-$0.38 in mid-August 2026) and elevated short volume ratio (~40% of session volume, per FINRA data).
▼ bearish
Impact
PhasePhase 1/2 (estimated — Phase 2 topline data expected H2 2028)
Time to marketUnknown — Phase 2 data not expected until H2 2028, putting potential approval several years beyond that if results are positive.

RXC008 Updated Sep 13

What to watch

For SKYE shareholders, the value thesis has been fundamentally altered by the Redx reverse merger, existing holders are being diluted to ~5.38% ownership. RXC008's next meaningful catalyst (Phase 2 topline data) is not expected until H2 2028, roughly two years out. Investors should assess whether the CVRs offered to legacy SKYE holders have any real value and monitor the shareholder vote on the merger.

Bull case
  • $125M in committed PIPE financing provides a clear funding path through Phase 2 readout, reducing dilution risk from future capital raises.
  • Fibrosis is a large, underserved market with high unmet need, positive Phase 2 data could unlock significant value for the combined entity.
  • Analyst consensus shows 9 Buy/Strong Buy ratings vs 3 Hold, with a mean price target of $68 (implying ~2,250% upside from the $1.86 reference price).
Bear case
  • Pre-transaction Skye shareholders will own only ~5.38% of the combined company, extreme dilution that destroys value for existing holders.
  • RXC008 is still in early-stage development with no Phase 2 data until H2 2028, binary clinical risk is years away and the drug could fail.
  • Skye was already facing Nasdaq delisting for failing minimum equity requirements, signaling financial distress before the reverse merger.
● neutral
Impact
PhasePhase 2a (completed)
Time to marketUnknown — Phase 2a completed, Phase 2b not yet initiated; a partnership-dependent path with no announced timeline

RXC007 zelasudil Updated Oct 26

What to watch

RXC007 has no scheduled binary catalyst; the key event to watch is the Skye-Redx merger closing (expected Q4 2026) and whether Fibrx announces a partnering deal for RXC007 afterwards. Any partnership terms (upfront, milestones) could serve as a partial valuation floor for this asset.

Bull case
  • RXC007 (zelasudil) is a highly selective ROCK2 inhibitor that showed encouraging Phase 2a data in IPF: well-tolerated with a numerical 47% reduction in FVC decline at the 20mg BID dose and evidence of anti-fibrotic activity sustained through 24 weeks in an open-label extension.
  • The combined Fibrx entity is well-capitalized ($125M in committed financing, projected to fund operations into 2029), providing runway to advance or partner RXC007 without near-term financing risk.
  • RXC007 has potential in multiple large fibrotic indications beyond IPF, including cancer-associated fibrosis and MASH, expanding its total addressable market if successfully developed.
Bear case
  • RXC007 is a secondary asset in the combined Fibrx pipeline, the lead program is RXC008 for fibrostenotic Crohn's, and RXC007 is explicitly positioned for out-licensing/partnering, meaning the company does not plan to bear full development cost or capture all upside.
  • The Phase 2a data, while positive, showed only numerical (not statistically significant) reduction in FVC decline, a 'signal searching' study that needs confirmation in a larger Phase 2b trial, which has not been initiated or dated.
  • Pre-transaction Skye shareholders were diluted to ~5.38% of the combined entity per the Aug 14, 2026 transaction terms; massive insider selling in Sept 2026 by 10% owners (5AM Partners, Andrew Schwab) at ~$1.61/share suggests insiders are exiting post-merger.